This trial is conducted in Africa. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 70 in healthy male subjects.

Inclusion Criteria:

• Considered generally healthy upon completion of medical history and physical
• examination, as judged by the investigator
• Body Mass Index (BMI) between 19-29 kg/m^2 (both inclusive)
• Minimum body weight of 65 kg
• Fasting blood glucose between 3.8-6.0 mmol/L
• Glycohemoglobin (HbA1c) below 6.4 %
• Non-smokers

Exclusion Criteria:

• Clinically significant abnormal hematology, biochemistry, urinalysis or ECG (electrocardiogram) screening tests, as judged by the investigator
• A history of any illness that, in the opinion of the Investigator and/or Sponsor, might confound the results of the study or pose additional risk in administering the investigational product to the subject
• History of or current addiction to alcohol or drugs of abuse as determined by the investigator (positive drug/alcohol abuse screen)
• Hepatitis B or C
• Subjects with a first-degree relative with diabetes mellitus
• Known or suspected allergy to trial product or related products
• Smoking during the past three months